Stockscreener 앱 받기
0.417
0.76%
-0.0032
시간 외 거래:
.42
0.003
+0.72%
전일 마감가:
$0.4202
열려 있는:
$0.4325
하루 거래량:
426.71K
Relative Volume:
0.55
시가총액:
$24.81M
수익:
$2.06M
순이익/손실:
$-19.80M
주가수익비율:
-0.5789
EPS:
-0.7203
순현금흐름:
$-20.12M
1주 성능:
-18.68%
1개월 성능:
-26.83%
6개월 성능:
+11.08%
1년 성능:
-66.10%
1일 변동 폭
$0.4117
$0.4532
1주일 범위
$0.3305
$0.5199
52주 변동 폭
$0.3067
$1.34
Femasys Inc Stock (FEMY) Company Profile
명칭
Femasys Inc
전화
770-500-3910
주소
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
0.417 | 25.00M | 2.06M | -19.80M | -20.12M | -0.7203 |
ISRG
Intuitive Surgical Inc
|
464.45 | 163.73B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
156.34 | 44.73B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
75.51 | 36.73B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
44.00 | 36.12B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
222.85 | 32.70B | 5.40B | 1.49B | 1.78B | 10.12 |
Femasys Inc Stock (FEMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-20 | 개시 | Laidlaw | Buy |
Femasys Inc 주식(FEMY)의 최신 뉴스
FEMASYS (FEMY) COO awarded 150,000 stock options at $0.38 exercise price - Stock Titan
Femasys (FEMY) COO John Canning discloses ownership of 30,000 shares - Stock Titan
Femasys Names John Canning as New Chief Operating Officer - tipranks.com
Femasys Inc. Appoints John Canning as Chief Operating Officer, Effective March 30, 2026 - marketscreener.com
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth - Bitget
Femasys names John Canning as chief operating officer - investing.com
Femasys names John Canning as Chief Operating Officer - tradingview.com
Veteran MedTech leader John Canning joins Femasys (NASDAQ: FEMY) as COO - Stock Titan
Medtech veteran joins Femasys to scale fertility, birth control products - Stock Titan
Femasys earnings beat by $0.12, revenue fell short of estimates - ca.investing.com
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update - National Today
Femasys (NASDAQ: FEMY) advances FemBloc and FemaSeed women’s health platform - Stock Titan
Femasys 2025 sales jump on FemBloc demand - TradingView
Femasys (NASDAQ: FEMY) details 2025 results and FemBloc FINALE trial - Stock Titan
Femasys Inc expected to post a loss of 9 cents a shareEarnings Preview - tradingview.com
Permanent birth control developer starts U.S. trial, cash lasts into Q3 2026 - Stock Titan
FEMY Should I Buy - intellectia.ai
Femasys (FEMY) CFO receives 34,122 Series D-1 warrants at $0.58 - Stock Titan
Femasys (NASDAQ: FEMY) director receives 102,366 Series D-1 stock warrants - Stock Titan
Board seeks reverse split, Nasdaq‑rule approval for issuances (FEMY) - Stock Titan
Femasys (NASDAQ: FEMY) director discloses notes, warrants and share stake - Stock Titan
Femasys Inc. Enters Omnibus Amendment and Issues Series D-1 Warrants – SEC 8-K Filing March 2026 - Minichart
Femasys amends warrants and notes, appoints new director to board By Investing.com - Investing.com South Africa
Femasys amends warrants and notes, appoints new director to board - Investing.com
Femasys (NASDAQ: FEMY) director receives stock options for 35,200 shares - Stock Titan
Femasys Amends Financing Terms and Issues New Warrants - TipRanks
Femasys enters omnibus amendment and consent agreement on March 19, 2026SEC filing - marketscreener.com
Femasys Enters Omnibus Amendment And Consent Agreement On March 19, 2026SEC Filing - TradingView
Femasys Amends Notes and Warrants; Issues 16.38M New Warrants at $0.58 to Holders - tradingview.com
Femasys (FEMY) grants 16.4M Series D-1 warrants and appoints new independent director - Stock Titan
Femasys Inc. announced that it has received $12 million in funding - marketscreener.com
Femasys appoints anesthesiologist to board of directors By Investing.com - Investing.com South Africa
PharmaCyte Biotech (PMCB) logs neutral Form 4 as 10% FEMASYS (FEMY) owner - Stock Titan
Femasys (NASDAQ: FEMY) director Joshua Silverman files neutral Form 4 - Stock Titan
PharmaCyte Biotech (FEMY) reports 7.87% stake including warrants - Stock Titan
Femasys Inc. Appoints Dr. Kenneth D. Eichenbaum to Board of Directors - marketscreener.com
Femasys appoints anesthesiologist to board of directors - Investing.com
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors - Bitget
Femasys Inc. Appoints Kenneth D. Eichenbaum, M.D., M.S.E., to Board of Directors - Quiver Quantitative
Femasys appoints Dr. Kenneth D. Eichenbaum to board of directors - marketscreener.com
Femasys Appoints Dr. Kenneth D. Eichenbaum To Board Of Directors - TradingView
Femasys begins enrollment in pivotal trial for FemBloc device - Investing.com Nigeria
Jeremy Alexander Sipos Net Worth (2026) - GuruFocus
Femasys gets FDA OK for final FemBloc trial, secures $12M financing, stock surges - MSN
Femasys Stock Sparks Retail Frenzy After FDA Clears Final Phase Of FemBloc Trial And $58M Financing - MSN
Femasys begins enrollment in pivotal trial for FemBloc device By Investing.com - Investing.com Australia
Non-surgical permanent birth control FemBloc begins final U.S. trial - Stock Titan
Femasys Inc. (NASDAQ:FEMY) Receives $5.50 Average Price Target from Analysts - Defense World
PMCB Stock Jumps 25% After Company Sells Stake In Femasys - Stocktwits
Femasys (NASDAQ:FEMY) Now Covered by Analysts at Lake Street Capital - Defense World
Lake Street initiates Femasys stock coverage with buy rating By Investing.com - Investing.com Australia
Femasys Inc (FEMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.76%
자본화:
|
볼륨(24시간):